Achieve Life Sciences (ACHV) Posts Quarterly Earnings Results, Beats Estimates By $0.57 EPS

Achieve Life Sciences (NASDAQ:ACHV) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.57, Fidelity Earnings reports.

Shares of Achieve Life Sciences stock traded down $0.01 during trading hours on Friday, hitting $2.07. The company’s stock had a trading volume of 74,464 shares, compared to its average volume of 440,980. Achieve Life Sciences has a 12-month low of $1.85 and a 12-month high of $32.00. The company has a market capitalization of $10.24 million, a price-to-earnings ratio of -0.09 and a beta of 2.28.

Separately, LADENBURG THALM/SH SH started coverage on Achieve Life Sciences in a research report on Monday, August 20th. They issued a “buy” rating and a $12.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Featured Article: Hedge Funds – How They Work For Investors

Earnings History for Achieve Life Sciences (NASDAQ:ACHV)

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with's FREE daily email newsletter.

Leave a Reply